INTERVENTIONS FOR VALVULAR DISEASE AND HEART FAILURE

One-year outcomes with two suture-mediated closure devices to achieve access-site haemostasis following transfemoral transcatheter aortic valve implantation

EuroIntervention 2016;12:1298-1304. DOI: 10.4244/EIJV12I10A213

Julinda Mehilli1,2*, MD; David Jochheim1,2, MD; Mohamed Abdel-Wahab3, MD; Konstantinos D. Rizas1, MD; Hans Theiss1, MD; Nina Spenkuch1; Magda Zadrozny1, MD; Moritz Baquet1, MD; Mohamed El-Mawardy3, MD; Takao Sato3, MD; Philipp Lange1, MD; Christian Kuppatt1,2, MD; Martin Greif1, MD; Jörg Hausleiter1,2, MD; Axel Bauer1,2, MD; Florian Schwarz2,4, MD; Maximilian Pichlmaier2,5, MD; Christian Hagl2,5, MD; Gert Richardt3, MD; Steffe

1. Cardiology Department, Munich University Clinic, Ludwig-Maximilians University, Munich, Germany; 2. Munich Heart Alliance at DZHK, Munich, Germany; 3. Herzzentrum, Segeberger Kliniken GmbH, Bad Segeberg, Germany; 4. Radiology Department, Munich Univers

Aims: In the current study we assess the impact of two different access-site suture-mediated closure devices (SMCD), ProGlide and Prostar, on vascular and bleeding complications after tra

Forgot your password?

No account yet? Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

access siteclosure devicetavitransfemoralvascular complication

Interventions for valvular diseaseTAVIVascular access and bleeding

Share on Facebook Share on Twitter Share on Linkedin